Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 82, Issue 4 , Pages 211-218 , April 2010

Regulation of hepatic gene expression by saturated fatty acids

  • T. Vallim

      Affiliations

    • Current address: Departments of Biological Chemistry and David Geffen School of Medicine at UCLA, 675 Charles E Young Drive South, Los Angeles, CA 90095, USA.
    • ,
  • A.M. Salter

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +441159516120.

References 

  1. Jump DB. n-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr. Opin. Lipidol. 2008;19:242–247
  2. Salter AM, Tarling EJ. Regulation of gene transcription by fatty acids. Animal. 2007;1:1314–1320
  3. Sampath H, Ntambi J. Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu. Rev. Nutr. 2005;25:317–340
  4. Packard CJ, Shepherd J. Physiology of the lipoprotein transport system: an overview of lipoprotein metabolism. In:  Betteridge DJ,  Illingworth DR,  Shepherd J editor. Lipoproteins in Health and Disease. London: Arnold; 1999;p. 3–316
  5. Salter AM, Mangiapane EH. The lipoproteins. Diet, Lipoprotein and Coronary Heart Disease: A Biochemical Perspective. Nottingham: Nottingham University Press; 1999;pp. 41–66
  6. Babin PJ, Gibbons GF. The evolution of plasma cholesterol: direct utility or a “spandrel” of hepatic lipid metabolism. Prog. Lipid Res. 2009;48:73–91
  7. Rye K-A, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and ant-atherogenic properties of HDL. J. Lipid Res. 2009;50:S195–S200
  8. White DA, Bennett AJ, Billett MA, Salter AM. The assembly of triacylglycerol-rich lipoproteins; an essential role for the microsomal triacylglycerol transfer protein. Br. J. Nutr. 1998;80:219–229
  9. Gambino R, Cassader M, Pagano G, Durazzo M, Musso G. Polymophism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH. Hepatology. 2007;45:1097–1107
  10. J. Ye, J.Z. Li, Y. Liu et al., Cideb, an ER- and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B, Cell Metab. 9 (2009) 177–190.
  11. Hussain MM, Strickland DK, Bakillah A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 1999;19:141–172
  12. Trigatti TB, Kreiger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003;23:1732–1738
  13. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells and blood. Proc. Natl. Acad. Sci. USA. 1999;96:11041–11048
  14. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete programme of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 2002;109:1125–1131
  15. Salter AM, White DA. Effects of dietary fat on cholesterol metabolism: regulation of plasma LDL concentrations. Nutr. Res. Rev. 1996;9:241–257
  16. Anon, The diet and all-causes death rate in the Seven Countries Study, Lancet 318 (8237) (1981) 57–61.
  17. Keys A, Anderson JT, Grande F. Serum cholesterol response to changes in diet IV. Particular saturated fatty acids in the diet. Metabolism. 1965;14:776–787
  18. Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. Am. J. Clin. Nutr. 1965;17:281–295
  19. Mensink RP, Katan MB. Effects of dietary fatty acids on serum lipds and lipoproteins. A meta-analysis of 27 trials. Arterioscler. Thromb. 1992;12:911–919
  20. Mensink RP, Zock PL, Kester ADM, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins,: a meta-analysis of 60 controlled trials. Am. J. Clin. Nutr. 2003;77:1146–1155
  21. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin. Sci. 2008;115:141–150
  22. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 2009;48:1–26
  23. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin. Sci. 2009;116:539–564
  24. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100
  25. Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome:an update. World J. Gastroenterol. 2008;14:185–192
  26. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. Mech. Dis. 2010;5:145–171
  27. Day CP, James OF. Steatohepatitis: a tale of two “hits”?. Gastroenterology. 1998;114:842–845.
  28. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J. Mol. Med. 2009;87:679–695
  29. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation. 2004;109:433–438
  30. Donnelly KL, Smith CI, Schearzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with non-alcoholic fatty liver disease. J. Clin. Invest. 2005;115:1343–1351
  31. Oosterveer MH, van Dijk TH, Tietge UJF, et al. High fat feeding induces hepatic fatty acid elongation in mice. PLoS ONE. 2009;4(6):e6066
  32. Lin J, Yang R, Tarr PT, et al. Hyerlipidemic effects of dietary saturated fats mediated through PGC-1β coactivation of SREBP. Cell. 2005;120:261–273
  33. Sampath H, Miyazaki M, Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase-1 mediates the prolipogenic effects of dietary saturated fat. J. Biol. Chem. 2007;282:2483–2493
  34. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000;14:121–141
  35. Desvergne B, Wahli W. Peroxisome proliferators-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999;20:649–688
  36. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115:518–533
  37. Krey G, Braissant O, L’Horset F, et al. Fatty acids, eicosanoids, and hypolipidemic agents identified a sligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 1997;11:779–791
  38. Kliewer SA, Sundeth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and β. Proc. Natl. Acad. Sci. USA. 1997;94:4318–4323
  39. Chakravarthy MV, Lodhi IJ, Yin L, et al. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell. 2009;138:476–488
  40. Janowski BA, Grogan MJ, Jones SA SA, et al. Structural requirements of ligands for the oxysterol liver X receptors, LXRα and LXR®. Proc. Natl. Acad. Sci. 1999;96:266–271
  41. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 2000;16:459–481
  42. Geyeregger R, Zeyda M, Stulnig TM. Liver X receptors in cardiovascular and metabolic disease. Cell. Mol. Life Sci. 2006;63:524–539
  43. Peet DJ, Turley SD, Ma W, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell. 1998;93:693–704
  44. Laffitte BA, Chao LC, Li J, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc. Natl. Acad. Sci. USA. 2003;100:5419–5424
  45. Cao G, Liang Y, Broderick CL, et al. Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J. Biol. Chem. 2003;278:1131–1136
  46. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science. 2009;325:100–104
  47. Hannah VC, Ou J, Luong A, Goldstein JL, Brown MS. Unsaturated fatty acids downregulate SREBP isoforms 1a and 1c by two mechanisms. J. Biol. Chem. 2001;276:4365–4372
  48. Yoshikawa T, Shimano H, Amemiya-Kudo M, et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 2001;21:2991–3000
  49. Yoshikawa T, Shimano H, Yahagi N, et al. Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J. Biol. Chem. 2002;277:1705–1711
  50. Brown MS MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells and blood. Proc. Natl. Acad. Sci. USA. 1999;96:11041–11048
  51. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete programm of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 2002;109:1125–1131
  52. Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004;86:839–848
  53. Goldstein JL JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35–46
  54. Sun L-P L-P, Li L, Goldstein JL, Brown MS. Insig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro. J. Biol. Chem. 2005;280:26483–26490
  55. Nohturfft A, Yabe D, Goldstein JL, Brown MS, Espenshade PJ. Regulated step in cholesterol feedback localized to budding of SCAP from ER membranes. Cell. 2000;102:315–323
  56. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, et al. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs to the ER. Cell. 2002;110:489–500
  57. Lange Y, Steck TL, Ye J, Lanier MH, Molugu V, Ory D. Regulation of fibroblast mitochondrial 27-hydroxycholesterol production by active plasma membrane cholesterol. J. Lipid Res. 2009;50:1881–1888
  58. Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS. Switch-like control of SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance. Cell Metab. 2008;8:512–521
  59. Sheng Z, Otani H, Brown MS, Goldstein JL. Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. Proc. Natl. Acad. Sci. USA. 1995;92:935–938
  60. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano N. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J. Clin. Invest. 2000;101:2331–2339
  61. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 1996;98:1575–1584
  62. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J. Clin. Invest. 1997;99:846–854
  63. Horton JD, Bashmakov Y, Shimomura I, Shimano H H. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl. Acad. Sci. USA. 1998;95:5987–5992
  64. Worgall TS, Sturley SL, Soe T, Osborne TF, Deckelbaum RJ. Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of sterol regulatory element binding protein. J. Biol. Chem. 1998;273:23537–23540
  65. Hannah VC, Ou J, Luong A, Goldstein JL, Brown MS. Unsaturated fatty acids downregulate SREBP isoforms 1a and 1c by two mechanisms. J. Biol. Chem. 2001;276:4365–4372
  66. Yoshikawa T, Shimano H, Amemiya-Kudo M, et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 2001;21:2991–3000
  67. Yoshikawa T, Shimano H, Yahagi N, et al. Polyunsaturated fatty acids suppress sterol regulatory element-binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J. Biol. Chem. 2002;277:1705–1711
  68. Tarling E, Salter A, Bennett A. Transcriptional regulation of human SREBP-1c (sterol-regulatory-element-binding protein-1c): a key regulator of lipogenesis. Biochem. Soc. Trans. 2004;32:107–109
  69. Yoshikawa T, Ide T, Shimano H, et al. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signalling. Mol. Endocrinol. 2003;17:1240–1254
  70. Botolin D, Wang Y, Christian B, Jump DB. Docosahexaenoic acid (22:6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 26S proteasome-dependent pathways. J. Lipid Res. 2006;47:181–192
  71. Woollett LA, Spady DK, Dietschy JM. Regulatory effects of the saturated fatty acids 6:0 through 18:0 on hepatic low density lipoprotein receptor activity in the hamster. J. Clin. Invest. 1992;89:1133–1141
  72. Spady DK, Woollett LA, Dietschy JM. Regulation of plasma LDL-cholesterol levels by dietary cholesterol and fatty acids. Annu. Rev. Nutr. 1993;13:355–381
  73. Bennett AJ, Billett MA, Salter AM, et al. Modulation of hepatic apolipoprotein-b, 3-hydroxy-3-methylglutaryl-coa reductase and low-density-lipoprotein receptor messenger-RNA and plasma-lipoprotein concentrations by defined dietary fats—comparison of trimyristin, tripalmitin, tristerin and triolein. Biochem. J. 1995;311:167–173
  74. Salter AM, Mangiapane EH, Bennett AJ, et al. The effect of different dietary fatty acids on lipoprotein metabolism: concentration-dependent effects of diets enriched in oleic, myristic, palmitic and stearic acids. Br. J. Nutr. 1998;79:195–202
  75. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatisis research. Int. J. Exp. Pathol. 2006;87:1–16
  76. Daumerie CM, Woollett LA, Dietschy JM. Fatty acids regulate hepatic low density lipoprotein receptor activity through redistribution of intracellular cholesterol pools. Proc. Natl. Acad. Sci. USA. 1992;89:10797–10801
  77. Datta S, Osborne TF. Activation domains from both monomers contribute to transcriptional stimulation of sterol regulatory element-binding protein dimmers. J. Biol. Chem. 2005;280:3338–3345
  78. Bennett MK, Seo Y-K, Datta S, Shin D-J, Osborne TF. Selective binding of sterol regulatory element-binding protein isoforms and co-regulatory proteins to promoters for lipid metabolic genes in liver. J. Biol. Chem. 2008;283:15628–15637

PII: S0952-3278(10)00060-8

doi: 10.1016/j.plefa.2010.02.016

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 82, Issue 4 , Pages 211-218 , April 2010

Article Tools

* Image Usage & Resolution